The Curious Case of Wuhan’s Institute of Virology and Remdesivir

Thomas Moga, Bloomfield Hills-based Senior Counsel in Dykema’s Intellectual Property Practice Group, authored the Life Sciences Intellectual Property Review article, “The curious case of Wuhan’s Institute of Virology and remdesivir.” 

In the article, Moga described China’s patent system and a fourth amendment to the system which takes effect on June 1, 2021, and provides new and expanded protections, some directed at biotechnology and pharmaceutical products. He also laid out the patent timeline for the Wuhan Institute of Virology and Gilead Science’s antiviral pharmaceutical, remdesivir. 

LSIPR subscribers may read the entire article here.